Sickle cell advocates urge the legislature to declare disease a public‑health priority and expand services

A large, multi‑panel portion of the hearing focused on bills H1346 and S788 to improve sickle cell care. Leaders from the Massachusetts Sickle Cell Association, clinicians from major medical centers and people with lived experience asked the committee to report the bills favorably and to prioritize the disease as a statewide public‑health concern.

Jackie Haley (Massachusetts Sickle Cell Association) described persistent gaps in provider education, care coordination and resources. Pediatric and adult hematologists highlighted the disease’s severe complications (pain crises, stroke, acute chest syndrome) and said recent therapeutic advances — including curative stem‑cell and gene therapies — create urgent needs for fertility‑preservation coverage and broader care coordination. Dr. Philippa Sprint (pediatric hematologist) and other clinicians emphasized that historic underinvestment has left the community underserved and that a statewide registry and steering committee would support evidence‑based planning and better outcomes.

Multiple patients and family members provided personal testimony about emergency‑room stigma, difficulty securing appropriate pain treatment, transportation barriers, and the emotional and financial burdens caregivers carry. Clinicians and nurse navigators described programmatic work at Mass General and other centers that currently depends heavily on philanthropic funding and urged sustainable state support.

Committee members thanked witnesses and asked for more technical language and cost estimates; no committee vote was recorded at the hearing.